212 related articles for article (PubMed ID: 28150519)
21. Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.
Alexopoulos D; Barampoutis N; Gkizas V; Vogiatzi C; Tsigkas G; Koutsogiannis N; Davlouros P; Hahalis G; Nylander S; Parodi G; Xanthopoulou I
Clin Pharmacokinet; 2016 Mar; 55(3):359-67. PubMed ID: 26315810
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Husted SE; Storey RF; Bliden K; Tantry US; Høimark L; Butler K; Wei C; Teng R; Gurbel PA
Clin Pharmacokinet; 2012 Jun; 51(6):397-409. PubMed ID: 22515556
[TBL] [Abstract][Full Text] [Related]
23. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
24. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study.
Kubica J; Adamski P; Buszko K; Barańska M; Sikora J; Marszałł MP; Sobczak P; Sikora A; Kuliczkowski W; Fabiszak T; Kubica A; Jilma B; Alexopoulos D; Navarese EP
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):139-148. PubMed ID: 30689800
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention.
Marian MJ; Alli O; Al Solaiman F; Brott BC; Sasse M; Leesar T; Prabhu SD; Leesar MA
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28611098
[TBL] [Abstract][Full Text] [Related]
26. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
[TBL] [Abstract][Full Text] [Related]
27. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
[TBL] [Abstract][Full Text] [Related]
28. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.
Jeon HS; Kim MJ; Choi HY; Kim YH; Kim EH; Kim AR; Park HJ; Bae KS; Lim HS
Clin Ther; 2015 Mar; 37(3):563-73. PubMed ID: 25697420
[TBL] [Abstract][Full Text] [Related]
30. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers.
Teng R; Butler K
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):478-91. PubMed ID: 24755129
[TBL] [Abstract][Full Text] [Related]
32. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial.
Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Masci PG; Degrauwe S
Cardiol J; 2022; 29(4):591-600. PubMed ID: 35762079
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
[TBL] [Abstract][Full Text] [Related]
35. Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.
Ibrahim K; Shah R; Goli RR; Kickler TS; Clarke WA; Hasan RK; Blumenthal RS; Thiemann DR; Resar JR; Schulman SP; McEvoy JW
Thromb Haemost; 2018 Aug; 118(8):1409-1418. PubMed ID: 29972861
[TBL] [Abstract][Full Text] [Related]
36. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Li H; Guo J; Carlson GF; Teng R
Br J Clin Pharmacol; 2016 Aug; 82(2):352-61. PubMed ID: 27038001
[TBL] [Abstract][Full Text] [Related]
38. Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Sweeny JM; Angiolillo DJ; Franchi F; Rollini F; Waksman R; Raveendran G; Dangas G; Khan ND; Carlson GF; Zhao Y; Teng R; Mehran R
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28356282
[TBL] [Abstract][Full Text] [Related]
39. The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study.
Ratcovich H; Sadjadieh G; Andersson HB; Frydland M; Wiberg S; Dridi NP; Kjaergaard J; Holmvang L
EuroIntervention; 2017 Feb; 12(14):1782-1788. PubMed ID: 28216475
[TBL] [Abstract][Full Text] [Related]
40. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Thomas MR; Angiolillo DJ; Bonaca MP; Ajjan RA; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Sabatine MS; Storey RF
Thromb Haemost; 2017 May; 117(5):940-947. PubMed ID: 28300867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]